Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 and Zilovertamab Vedotin in R/R DLBCL
NCT07917754Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Primary completion
- Mar 2037
01
Overview
Phase 3, randomised, open-label trial of CN201 and zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity at 42 days, Adverse Event at 53 months and 3 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CN201zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07917754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917754.